Intravenous Immunoglobulin as a treatment for SLE with severe, refractory cutaneous involvement requiring hospitalization (Sengupta et al., 2023)

Published: 12 February 2024| Version 4 | DOI: 10.17632/pkjspywndt.4
Contributor:
Chirag Vasavda

Description

Supplemental Figures and Tables reporting patient demographics and clinical characteristics and dermatologic findings. Supplemental Figure 1. Acute cutaneous lupus erythematosus requiring hospitalization (Case 1). Supplemental Figure 2. Rapidly worsening DLE/SCLE before and after IVIg treatment (Case 2). Supplemental Figure 3. Acute cutaneous lupus erythematosus requiring hospitalization (Case 3). Supplemental Table 1. Patient summary and clinical characteristics.

Files

Institutions

Johns Hopkins Medicine

Categories

Dermatology, Rheumatology, Autoimmune Rheumatic Disease, Systemic Lupus Erythematosus

Licence